Skip to main content

DESAGREGASAS HUMANAS COMO UNA HERRAMIENTA TERAPEUTICA EN NEURODEGENERACION

BFU2016-75983-P

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulation of Human Hsc70 ATPase and Chaperone Activities by Apg2: Role of the Acidic Subdomain

  • Cabrera, Yovana
  • Dublang, Leire
  • Fernández-Higuero, José Ángel
  • Albesa-Jové, David
  • Lucas, María
  • Viguera, Ana Rosa
  • Guerin, Marcelo E.
  • Vilar, Jose M. G.
  • Muga, Arturo
  • Moro, Fernando
Protein aggregate reactivation in metazoans is accomplished by the combined activity of Hsp70, Hsp40 and Hsp110 chaperones. Hsp110s support the refolding of aggregated polypeptides acting as specialized nucleotide exchange factors of Hsp70. We have studied how Apg2, one of the three human Hsp110s, regulates the activity of Hsc70 (HspA8), the constitutive Hsp70 in our cells. Apg2 shows a biphasic behavior: at low concentration, it stimulates the ATPase cycle of Hsc70, binding of the chaperone to protein aggregates and the refolding activity of the system, while it inhibits these three processes at high concentration. When the acidic subdomain of Apg2, a characteristic sequence present in the substrate binding domain of all Hsp110s, is deleted, the detrimental effects occur at lower concentration and are more pronounced, which concurs with an increase in the affinity of the Apg2 mutant for Hsc70. Our data support a mechanism in which Apg2 arrests the chaperone cycle through an interaction with Hsc70(ATP) that might lead to premature ATP dissociation before hydrolysis. In this line, the acidic subdomain might serve as a conformational switch to support dissociation of the Hsc70:Apg2 complex., This work was supported by the MINECO Contract BFU2016-77427-C2-2-R and Severo Ochoa Excellence Accreditation (SEV-2016-0644) to M.E.G., FIS2015-68722-R (MICINN/FEDER) to J.M.G.V., and IT709-13 (Basque Government) and MINECO BFU2016-75983-P (AEI/FEDER, UE) to A.M. and F.M.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fine-tuning of the Hsc70-based Human Protein Disaggregase Machinery by the Distinctive C-terminal Extension of Apg2

  • Cabrera, Yovana
  • Bernardo-Seisdedos, Ganeko
  • Dublang, Leire
  • Albesa-Jové, David
  • Orozco, Natalia
  • Viguera, Ana Rosa
  • Millet, Óscar
  • Muga, Arturo
  • Moro, Fernando
Apg2, one of the three cytosolic Hsp110 chaperones in humans, supports reactivation of unordered and ordered protein aggregates by Hsc70 (HspA8). Together with DnaJB1, Apg2 serves to nucleate Hsc70 molecules into sites where productive entropic pulling forces can be developed. During aggregate reactivation, Apg2 performs as a specialized nucleotide exchange factor, but the origin of its specialization is poorly defined. Here we report on the role of the distinctive C-terminal extension present in Apg2 and other metazoan homologs. We found that the first part of this Apg2 subdomain, with propensity to adopt α-helical structure, interacts with the nucleotide binding domain of Hsc70 in a nucleotide-dependent manner, contributing significantly to the stability of the Hsc70:Apg2 complex. Moreover, the second intrinsically disordered segment of Apg2 C-terminal extension plays an important role as a downregulator of nucleotide exchange. An NMR analysis showed that the interaction with Hsc70 nucleotide binding domain modifies the chemical environment of residues located in important functional sites such as the interface between lobe I and II and the nucleotide binding site. Our data indicate that Apg2 C-terminal extension is a fine-tuner of human Hsc70 activity that optimizes the substrate remodeling ability of the chaperone system., .C. and L.D. were recipients of UPV/EHU and MEC FPU predoctoral fellowships, respectively. We thank Fundación Biofisika Bizkaia for supporting N.O. This work was supported by CTQ2016-76941-R (MINECO), Fundación Biofísica Bizkaia, the Basque Excellence Research Centre (BERC) of the Basque Government and Fundación BBVA to D.A.-J., and BFU2016-75983-P and PID2019-111068 GB-100 (MCI/AEI/FEDER, UE) grants from Spanish Government to A.M. and F.M. and IT1745-22 from Basque Government to F.M., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach

  • Dublang, Leire
  • Underhaug, Jarl
  • Flydal, Marte I.
  • Velasco-Carneros, Lorea
  • Maréchal, Jean Didier
  • Moro, Fernando
  • Boyano, María Dolores
  • Martínez, Aurora
  • Muga, Arturo
Heat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70 family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds, the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations indicate that this compound interacts with regions located in the nucleotide-binding domain and the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium bromide for cancer treatment appears as a promising novel therapeutic approach., This study was funded by grants BFU2016-75983-P and PID2019-111068GB-100 (AEI/FEDER/UE) from MINECO to F.M. and A.M. (Arturo Muga) and IT1201-19 from the Basque Government to F.M. Support from the Research Council of Norway (RCN, Grant FRIMEDBIO 261826/F20), the Western Norway Regional Health Authority (912246 to A.M. (Aurora Martinez) and M.I.F.), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Label-Free, Multiplexed, Single-Molecule Analysis of Protein–DNA Complexes with Nanopores

  • Celaya, Garbiñe
  • Perales-Calvo, Judit
  • Muga, Arturo
  • Moro, Fernando
  • Rodríguez-Larrea, David
Protein interactions with specific DNA sequences are crucial in the control of gene expression and the regulation of replication. Single-molecule methods offer excellent capabilities to unravel the mechanism and kinetics of these interactions. Here, we develop a nanopore approach where a target DNA sequence is contained in a hairpin followed by a ssDNA. This system allows DNA–protein complexes to be distinguished from bare DNA molecules as they are pulled through a single nanopore detector, providing both equilibrium and kinetic information. We show that this approach can be used to test the inhibitory effect of small molecules on complex formation and their mechanisms of action. In a proof of concept, we use DNAs with different sequence patterns to probe the ability of the nanopore to distinguish the effects of an inhibitor in a complex mixture of target DNAs and proteins. We anticipate that the use of this technology with arrays of thousands of nanopores will contribute to the development of transcription factor binding inhibitors., This work was supported by grants SAF2014-58398-R and BFU2013-4759 from MINECO, BFU2016-75983-P (AEI/FEDER, UE), FEDER funding, the 2015 edition of the BBVA Foundation Grants for Researchers and Cultural Creators, and grant IT709-13 from the Basque Government. D.R.-L. is a recipient of a Ramon y Cajal Fellowship (RYC-2013-12799)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach

  • Dublang, Leire
  • Underhaug, Jarl|||0000-0003-0346-3986
  • Flydal, Marte I.
  • Velasco-Carneros, Lorea|||0000-0002-1296-9498
  • Maréchal, Jean-Didier|||0000-0002-8344-9043
  • Moro, Fernando
  • Boyano, Maria Dolores
  • Martinez, Aurora|||0000-0003-1643-6506
  • Muga, Arturo|||0000-0003-0345-6882
High levels of Heat shock proteins (Hsps) in specific cancers are usually linked to a poor prognosis, tumor progression, invasiveness, and resistance to treatment. Chaperone inhibition could therefore be toxic for cancer cells due to their high dependence on chaperone activity to survive. This study shows the potential to repurpose the small chemical compound pinaverium bromide, currently used to treat functional gastrointestinal disorders, as a possible antitumor drug since it displays a marked toxicity against two melanoma cell lines without affecting the viability of fibroblast and primary melanocytes. This compound interacts with structural regions shared by representatives of the Hsp70 and Hsp110 families, inhibiting the substrate remodeling ability of the Hsp70 system in vitro and in a cellular context. Heat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70 family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds, the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations indicate that this compound interacts with regions located in the nucleotide-binding domain and the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium bromide for cancer treatment appears as a promising novel therapeutic approach.